1. Summary of outcomes* reported by intervention.
| Interventions | Primary outcomes | Secondary outcomes | Adverse effects | Duration of hospitalization or quality of life outcomes | ||||||
| VA | Time to resolution of primary hemorrhage | Secondary hemorrhage | Risk of corneal blood staining | Risk of PAS formation | Risk of pathologic increase in IOP or glaucoma | Risk of optic atrophy | ||||
| Risk of rebleed | Time to rebleed | |||||||||
| Aminocaproic acid vs placebo | ||||||||||
| Oral aminocaproic acid | ||||||||||
| Christianson 1979 | Not reported | Partially reported** | Risk of rebleed reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Crouch 1976 | Long‐term VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Risk of corneal blood staining reported | Partially reported** | Not reported | Risk of optic atrophy reported | Not reported | Not reported |
| Kraft 1987 | Long‐term VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Persistent increases in IOP reported | Not reported | Adverse effects reported | Not reported |
| Kutner 1987 | Short‐term VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Persistent increases in IOP reported | Not reported | Adverse effects reported | Not reported |
| McGetrick 1983 | Final VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Not reported | Not reported | Adverse effects reported | Partially reported** |
| Teboul 1995 | Final VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Transient increases in IOP reported | Not reported | Not reported | Duration of hospitalization reported |
| Topical aminocaproic acid | ||||||||||
| Karkhaneh 2003 | Reported as NS | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Reported as NS | Not reported | Not reported | Not reported |
| Pieramici 2003 | Short‐term VA reported | Reported as NS | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Transient increases in IOP reported | Not reported | Adverse effects reported | Not reported |
| Low‐dose vs standard‐dose aminocaproic acid | ||||||||||
| Palmer 1986 | Final VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Transient increases in IOP reported | Not reported | Adverse effects reported | Duration of hospitalization reported |
| Oral vs topical aminocaproic acid | ||||||||||
| Crouch 1997 | Final VA reported | Not reported | Risk of rebleed reported | Time to rebleed reported | Risk of corneal blood staining reported | Partially reported** | Not reported | Risk of optic atrophy reported | Adverse effects reported | Not reported |
| Tranexamic acid vs control | ||||||||||
| Rahmani 1999 | Short‐term VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Transient increases in IOP reported | Not reported | Adverse effects reported | Duration of hospitalization reported |
| Sukumaran 1988 | Short‐term VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Vangsted 1983 | Short‐term VA reported | Partially reported** | Risk of rebleed reported | No rebleeds occurred | Risk of corneal blood staining reported | Not reported | Transient increases in IOP reported | Not reported | Not reported | Duration of hospitalization and days off work reported |
| Varnek 1980 | Partially reported** | Not reported | Risk of rebleed reported | Time to rebleed reported | Risk of corneal blood staining reported | Not reported | Transient increases in IOP reported | Risk of optic atrophy reported | Not reported | Duration of hospitalization reported |
| Welsh 1983 | Not reported | Partially reported** | Risk of rebleed reported | Not reported | Not reported | Not reported | Transient increases in IOP reported | Not reported | Adverse effects reported | Not reported |
| Aminomethylbenzoic acid vs placebo | ||||||||||
| Liu 2002 | Not reported | Not reported | Risk of rebleed reported | Not reported | Not reported | Not reported | Not reported | Not reported | Adverse effects reported | Not reported |
| Corticosteroids vs control | ||||||||||
| Oral corticosteroids | ||||||||||
| Rahmani 1999 | Short‐term VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Transient increases in IOP reported | Not reported | Adverse effects reported | Duration of hospitalization reported |
| Spoor 1980 | Final VA reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Risk of corneal blood staining reported | Risk of PAS formation reported | Transient increases in IOP reported | Not reported | Not reported | Not reported |
| Topical corticosteroids | ||||||||||
| Rakusin 1972 | Short‐term VA reported | Partially reported** | Risk of rebleed reported | Not reported | Partially reported** | Partially reported** | Not reported | Not reported | Not reported | Not reported |
| Zetterstrom 1969 | Short‐term VA reported | Not reported | Risk of rebleed reported | Not reported | Risk of corneal blood staining reported | Not reported | Transient increases in IOP reported | Risk of optic atrophy reported | Not reported | Duration of hospitalization reported |
| Oral aminocaproic acid vs oral prednisone | ||||||||||
| Farber 1991 | Short‐term VA reported | Partially reported** | Risk of rebleed reported | Not reported | Not reported | Not reported | Reported as NS | Not reported | Not reported | Not reported |
| Conjugated estrogen vs placebo | ||||||||||
| Spaeth 1966 | Partially reported** | Not reported | Risk of rebleed reported | Partially reported** | Risk of corneal blood staining reported | Partially reported** | Partially reported** | Not reported | Not reported | Not reported |
| Cycloplegics vs miotics | ||||||||||
| Bedrossian 1974 | Not reported | Days to resolution reported | Risk of rebleed reported | Time to rebleed reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Rakusin 1972 | Short‐term VA reported | Partially reported** | Risk of rebleed reported | Not reported | Reported as NS | Reported as NS | Not reported | Not reported | Not reported | Not reported |
| Aspirin vs observation | ||||||||||
| Marcus 1988 | Not reported | Not reported | Risk of rebleed reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Traditional Chinese medicine vs control treatment | ||||||||||
| Wang 1994 | Partially reported** | Partially reported** | Partially reported** | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Monocular vs binocular patching | ||||||||||
| Edwards 1973 | Final VA reported | Not reported | Risk of rebleed reported | Time to rebleed reported | Risk of corneal blood staining reported | Not reported | Risk of secondary glaucoma reported | Not reported | Not reported | Quality of life outcomes reported |
| Rakusin 1972 | Short‐term VA reported | Partially reported** | Risk of rebleed reported | Not reported | Reported as NS | Reported as NS | Not reported | Not reported | Not reported | Not reported |
| Ambulatory vs conservative treatment | ||||||||||
| Rakusin 1972 | Short‐term VA reported | Partially reported** | Risk of rebleed reported | Not reported | Reported as NS | Reported as NS | Not reported | Not reported | Not reported | Not reported |
| Read 1974 | Partially reported** | Days to resolution reported | Risk of rebleed reported | Partially reported** | Risk of corneal blood staining reported | Not reported | Transient increases in IOP reported | Not reported | Not reported | Not reported |
| Elevation of the head vs control | ||||||||||
| Zi 1999 | Not reported | Days to resolution reported | Not reported | Not reported | Not reported | Not reported | Risk of secondary glaucoma reported | Not reported | Not reported | Not reported |
*See Types of outcome measures for detailed descriptions of outcomes. **Noted as 'partially reported' if some information was reported, but it was insufficient for quantitative data analyses.
Abbreviations: IOP: intraocular pressure; NS: not significant; PAS: peripheral anterior synechiae; VA: visual acuity.